Paolo Tarantino: Important point by Erika Hamilton – common questions should derive from RCTs

Paolo Tarantino shared the following post by ESMO on X, adding the following:

“Important point by Erika Hamilton. A common questions from pts is: what should I take (or eat) to reduce my risk of recurrence? The answer to this question should not come from retrospective studies, often burdened by confounding bias, but should derive from RCTs. ”

Source: Paolo Tarantino/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
OncoDaily
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.